Doripenem (Doribax): the newest addition to the carbapenems.

Article Details

Citation Copy to clipboard

Greer ND

Doripenem (Doribax): the newest addition to the carbapenems.

Proc (Bayl Univ Med Cent). 2008 Jul;21(3):337-41.

PubMed ID

18628935 [ View in PubMed

]

Abstract

Carbapenems are a class of antimicrobials structurally related to penicillin. Doripenem, the newest agent in this class, was recently approved by the Food and Drug Administration for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Its spectrum of activity is similar to that of meropenem and imipenem/cilastatin. Some studies indicate that approximately 29% of carbapenem-resistant Pseudomonas aeruginosa isolates may remain sensitive to doripenem, although the clinical relevance of that finding has not been determined. Clinical studies, which have been published only in abstract form to date, have found doripenem to be similar to comparator agents. The most common adverse effects related to doripenem therapy were headache, nausea, diarrhea, rash, and phlebitis. Doripenem, like the other carbapenems, may also cause seizures. Because of the lack of published data, the lack of clear advantages over meropenem, and the increased cost compared with meropenem, doripenem will not be available for use at Baylor University Medical Center except by infectious diseases specialists.

DrugBank Data that Cites this Article

Drug Transporters

Drug	Transporter	Kind	Organism	Pharmacological Action	Actions
Doripenem	Solute carrier family 22 member 8	Protein	Humans	No	Substrate	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software